Torrelavega

Researchers are studying the use of bempedoic acid combined with ezetimibe and either rosuvastatin or atorvastatin, known as triple therapy, in adults with primary hypercholesterolemia or mixed dyslipidemia. The study aims to evaluate the effectiveness and safety of this combination in real-world clinical practice, focusing on lowering LDL cholesterol LDL-C levels. This is an observational study, meaning no drugs are administered by the study team instead, existing treatments are monitored. Participants are adults who have started triple therapy within the past four weeks and are followed for up to one year. The study looks at LDL-C changes after 8 weeks and 1 year of treatment, adherence to the therapy, side effects, and cardiovascular events such as heart attacks and strokes. No new treatments are given instead, researchers collect information on the participants ongoing treatments involving bempedoic acid, ezetimibe, and either rosuvastatin or atorvastatin. During the study, participants LDL-C levels, laboratory values, and treatment adherence are regularly reviewed. Researchers will also record any adverse events and track major cardiovascular events over the year. The primary measurement is the change in LDL-C from before treatment to 8 weeks after starting triple therapy. Participants health is followed through routine clinical assessments, and the study lasts for up to one year after beginning triple therapy.

Researchers are evaluating a new approach to prevent heart and blood vessel problems in patients with inflammatory rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and systemic lupus erythematosus. These patients have a 50% higher chance of cardiovascular events compared to the general population, and current risk scores often underestimate their true risk. This phase IV clinical trial aims to test if using carotid ultrasound to detect early artery disease can better identify patients at high risk and improve prevention. Participants aged 50 years and older with inflammatory rheumatic diseases and low-to-moderate cardiovascular risk will be randomly assigned to either receive a carotid ultrasound or follow standard care based on current guidelines. Those in the ultrasound group found to have carotid plaques will be classified as very high risk and started on high-intensity statin therapy to lower LDL cholesterol below 55 mgdL. Patients without plaques and those in the control group will receive care according to the European Society of Cardiology 2021 recommendations. The study will last 48 months with ongoing monitoring. Throughout the study, patients will have regular visits to track their health and treatment effects. Those needing lipid-lowering therapy will have monthly visits during treatment adjustment, then every six months until the study ends. All patients will be monitored for major cardiovascular events such as heart attacks, strokes, and hospitalizations over four years. Safety and side effects will also be evaluated, aiming to see if the ultrasound-based strategy better prevents heart problems compared to standard care.

The registry focuses on patients with venous thromboembolism VTE, including those often excluded from typical clinical trials such as pregnant women, elderly patients, and those with serious health conditions. It aims to improve medical knowledge and patient care by collecting detailed data on these patients clinical status and treatment outcomes. The project also seeks to develop predictive scores to identify patients at higher risk of complications from thromboembolic disease. This observational registry collects extensive information on patients diagnosed with VTE, including details on coexisting conditions, antithrombotic treatment type, dose, and duration, as well as outcomes during the first three months of therapy. It captures data on VTE recurrences, bleeding complications, and deaths, providing insights into real-world treatment and patient management. Participants provide informed consent and are followed for at least three months to monitor clinical outcomes. The registry supports physicians by giving access to data on patients with similar profiles to help manage complex cases. The main outcomes measured include VTE events and complications over a three-year period, supporting ongoing improvements in patient care and risk assessment.

Researchers are studying how inflammatory bowel disease IBD activity affects frailty in patients aged 60 years and older. This observational, multicenter, prospective, and longitudinal study aims to understand if frailty and related risks like hospitalization and mortality can be reversed with proactive treatment in frail patients with active IBD. The study also evaluates which frailty index best predicts complications in this population. At the start, four clinical frailty indices will be calculated for each participant, alongside recording clinical variables related to IBD and other health conditions. Patients will be followed through three visits at 3, 6, and 12 months, during which frailty, disease activity, treatment changes, adverse effects, hospitalizations, and mortality will be reassessed to track progress and outcomes. Participants will be involved in these visits where various assessments will be done, including measuring frailty and comorbidities and reviewing their IBD activity and treatments. The main outcomes include assessing the impact of IBD activity on frailty and how frailty affects hospitalization and mortality risk over a 12-month period. The study is led by the Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa and runs until May 2027.

Primary immune thrombocytopenia PIT, formerly called idiopathic thrombocytopenic purpura, is a disease where platelets are destroyed faster than they are made, leading to low platelet counts. The causes are not fully understood, and the disease affects patients differently, making diagnosis based on ruling out other causes. There is limited data on how common PIT is in Spain, so this study aims to better understand the characteristics and treatment of patients with PIT and other immune thrombocytopenias in Spain. This research is an observational, multicenter study collecting information from hospital patient records across Spain. It includes children from 2 months old and adults who have been monitored since 2015 with a diagnosis or suspicion of PIT or similar immune-related thrombocytopenia. The study gathers data on clinical features, lab results, and treatments received, without introducing any new treatments or interventions. Participants medical histories will be reviewed to describe their disease and treatment details. Researchers will analyze clinical and laboratory data from enrollment onwards, comparing it with past published ITP data and evaluating responses to first and subsequent treatments. The study is sponsored by the Fundacin Espaola de Hematologa y Hemoterapia and will continue collecting data until 2034.